1 active not recruiting, 1 available, 1 recruiting. 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Active not recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow IDRX-42: new trials by email Literature Review of IDRX-42 trials Research Report on IDRX-42
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy IDRX-42, Sunitinib - Gastrointestinal Neoplasms | Phase 3 | Recruiting | GlaxoSmithKline | 450 | 2025-12-03 | 2026-10-05 |
| First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors IDRX-42 - Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST) | Phase 1 | Active not recruiting | IDRX, Inc., a wholly owned subsidiary of GSK, LLC | 276 | 2022-08-03 | 2026-10-05 |
| Individual Patient Expanded Access for Velzatinib (GSK6042981) in Patients With Gastrointestinal Stromal Tumours With KIT Mutations Velzatinib (GSK6042981) - Gastrointestinal Neoplasms | Available | GlaxoSmithKline | 2026-09-17 |
Gastrointestinal Neoplasms (3) · Gastrointestinal Stromal Tumors (3) · Digestive System Diseases (1) · Gastrointestinal Diseases (1) · Neoplasm Metastasis (1)
GlaxoSmithKline (2) · IDRX, Inc., a wholly owned subsidiary of GSK, LLC (1)
Belgium (2) · China (2) · France (2) · Germany (2) · Italy (2) · Japan (2) · Netherlands (2) · South Korea (2) · Spain (2) · United Kingdom (2) · United States (2) · Australia (1) · Brazil (1) · Canada (1) · Hungary (1)
2025 (1)